Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area

Vaccine

Volumn 18, Issue 22, 2000, Pages 2399-2410

  Richie, Emily ^a,b   Punjabi, Narain H ^a   Sidharta, Yuwono ^c   Peetosutan, Kenny ^c   Sukandar, Melanie ^a   Wasserman, Steven S ^d   Lesmana, Murad ^b   Wangsasaputra, Ferry ^a   Pandam, Sri ^b   Levine, Myron M ^d   O'Hanley, Peter ^a,e   Cryz, Stanley J ^f   Simanjuntak, Cyrus H ^c  

^a US Naval Medical Research Unit No 2 Jakarta   (Indonesia)

^b Glenwood Life Counseling Center   (United States)

^c NATIONAL INSTITUTE OF HEALTH RESEARCH AND DEVELOPMENT   (Indonesia)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e IQVIA   (United States)

^f Berna Biotech AG   (Switzerland)

Author keywords

Cholera; Efficacy; Vaccine

Indexed keywords

CHOLERA VACCINE; LIVE VACCINE; PLACEBO;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHOLERA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN TISSUE; INDONESIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WORLD HEALTH ORGANIZATION;

EID: 0034014485     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00006-2     Document Type: Article

References (56)

1. Mintz E.D., Tauxe R.V., Levine M.M. The global resurgence of cholera. Noah N., Mahoney M. Communicable disease: epidemiology and control. 1998;63-104 Wiley, Chichester.
2. Glass R.I., Claeson M., Blake P.A., et al. Cholera in Africa: lessons on transmission and control for Latin America. Lancet. 338:1991;791-795.
3. Sanchez J.L., Taylor D.N. Cholera. Lancet. 349:1997;1825-1830.
4. Levine M.M., Kaper J.B. Live oral cholera vaccine: from principle to product. Bull. Inst. Pasteur. 93:1995;243-253.
5. Levine M.M., Nalin D.R., Craig J.P., et al. Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity. Trans. Roy. Soc. Trop. Med. Hyg. 73:1979;3-9.
6. Levine M.M., Black R.E., Clements M.L., et al. Duration of infection-derived immunity to cholera. J. Infect. Dis. 143:1981;818-820.
7. Levine M.M., Black R.E., Clements M.L., et al. Volunteer studies in development of vaccines against cholera and enterotoxigenic Escherichia coli: a review. Holme T., Holmgren J., Merson M.H., Mollby R. Acute enteric infections in children. New prospects for treatment and prevention. 1981;443-459 Elsevier/North-Holland Biomedical Press, Amsterdam.
8. Glass R.I., Becker S., Huq I., et al. Endemic cholera in rural Bangladesh, 1966-1980. Am. J. Epidemiol. 116:1982;959-970.
9. Clemens J.D., van Loon F., Sack D.A., et al. Biotype as determinant of natural immunising effect of cholera. Lancet. 337:1991;883-884.
10. Levine M.M., Kaper J.B., Herrington D., et al. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet. 2:1988;467-470.
11. Tacket C.O., Losonsky G., Nataro J.P., et al. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J. Infect. Dis. 166:1992;837-841.
12. Kenner J.R., Coster T.S., Taylor D.N., et al. Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1. J. Infect. Dis. 172:1995;1126-1129.
13. Migasena S., Pitisuttitham P., Prayurahong P., et al. Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults. Infect. Immun. 57:1989;3261-3264.
14. Su-Arehawaratana P., Singharaj P., Taylor D.N., et al. Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand. J. Infect. Dis. 165:1992;1042-1048.
15. Suharyono, Simanjuntak C., Witham N., et al. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children. Lancet. 340:1992;689-694.
16. Simanjuntak C.H., O'Hanley P., Punjabi N.H., et al. The safety, immunogenicity, and transmissibility of single-dose live oral cholera vaccine CVD 103-HgR in 24-59 month old Indonesian children. J. Infect. Dis. 168:1993;1169-1176.
17. Gotuzzo E., Butron B., Seas C., et al. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infect. Immun. 61:1993;3994-3997.
18. Lagos R., Avendaño A., Horwitz I., et al. Tolerancia e inmunogenicidad de una dosis oral de la cepa de Vibrio cholerae O1, viva-atenuada, CVD 103-HgR: estudio de doble ciego en adultos Chilenos. Rev. Med. Chile. 121:1993;857-863.
19. Lagos R., Avendaño A., Prado V., et al. Attenuated live oral cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O. Infect. Immun. 63:1995;707-709.
20. Lagos R., Losonsky G., Abrego P., et al. Tolerancia, immunogenicidad, excresión y transmisión de la vacuna anti-colera oral viva-atenuada, CVD 103-HgR, estudio pareado de doble ciego en niños Chilenos de 24-59 meses. Bol. Hosp. Infant. Mex. 53:1996;214-220.
21. Wasserman S.S., Losonsky G.A., Noriega F., et al. Kinetics of the vibriocidal antibody response to live oral cholera vaccines. Vaccine. 12:1994;1000-1003.
22. Perry R.T., Plowe C.V., Koumaré B., et al. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and non-infected adults in Mali. Bull. World Health Org. 76:1998;63-71.
23. Kotloff K.L., Wasserman S.S., O'Donnell S., et al. Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial. Infect. Immun. 60:1992;4430-4432.
24. Rennels M.B., Levine M.M., Daya V., et al. Selective vs nonselective media and direct plating vs enrichment technique in isolation of Vibrio cholerae: recommendations for clinical laboratories. J. Infect. Dis. 142:1980;328-331.
25. Kaper J.B., Morris J.G. Jr, Levine M.M. Cholera. Clin. Microbiol. Rev. 8:1995;48-86.
26. Lesmana M., Subekti D., Tjaniadi P., Pazzaglia G. Modified CAMP test for biogrouping Vibrio cholerae O1 strains and distinguishing them from strains of V. cholerae non-O1. J. Clin. Microbiol. 32:1994;235-237.
27. Benenson A.S., Saad A., Mosley W.H. Serological studies in cholera. The vibriocidal antibody response of cholera patients determined by a microtechnique. Bull. World Health Org. 38:1968;277-285.
28. Clements M.L., Levine M.M., Young C.R., et al. Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae. J. Infect. Dis. 145:1982;465-473.
29. Clopper C.J., Pearson E.S. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 26:1934;404-413.
30. Clemens J.D., Sack D.A., Harris J.R., et al. ABO blood groups and cholera: new observations on specificity of risk and modifications of vaccine efficacy. J. Infect. Dis. 159:1989;770-773.
31. Glass R.I., Holmgren J., Haley C.E., et al. Predisposition for cholera of individuals with O blood group. Possible evolutionary significance. Am. J. Epidemiol. 121:1985;791-796.
32. Tacket C.O., Losonsky G., Nataro J.P., et al. Extension of the volunteer challenge model to study South American cholera in a population of volunteers predominantly with blood group antigen O. Trans. Roy. Soc. Trop. Med. Hyg. 89:1995;75-77.
33. Cryz S.J., Levine M.M., Kaper J.B., et al. Randomized double-blind placebo controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in Swiss adults. Vaccine. 8:1990;577-580.
34. Holt E.A., Moulton L.H., Siberry G.K., Halsey N.A. Differential mortality by measles vaccine titer and sex. J. Infect. Dis. 168:1993;1087-1096.
35. Aaby P., Samb B., Simondon F., et al. Divergent mortality for male and female recipients of low-titer and high-titer measles vaccines in rural Senegal. Am. J. Epidemiol. 138:1993;746-755.
36. Losonsky G.A., Tacket C.O., Wasserman S.S., et al. Secondary Vibrio cholerae-specific cellular antibody responses following wild-type homologous challenge in people vaccinated with CVD 103-HgR live oral cholera vaccine: changes with time and lack of correlation with protection. Infect. Immun. 61:1993;729-733.
37. Levine M.M., Pierce N.F. Immunity and vaccine development. Barua D., Greenough W.B. III. Cholera. 1992;285-327 Plenum Medical Book Co, New York.
38. Taylor D.N., Tacket C.O., Losonsky G., et al. Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru. Infect. Immun. 65:1997;3852-3856.
39. Clemens J.D., Stanton B.F., Chakraborty J., et al. B subunit-whole cell and whole cell-only oral vaccines against cholera: studies on reactogenicity and immunogenicity. J. Infect. Dis. 155:1987;79-85.
40. Sack D.A., Clemens J.D., Huda S., et al. Antibody response after immunization with killed oral cholera vaccines during the 1985 vaccine field trial in Bangladesh. J. Infect. Dis. 164:1991;407-411.
41. Sanchez J.L., Trofa A.F., Taylor D.N., et al. Safety and immunogenicity of the oral, whole cell/recombinant B subunit cholera vaccine in North American volunteers. J. Infect. Dis. 167:1993;1446-1449.
42. Cryz S.J. Jr, Que J.U., Levine M.M., et al. Safety and immunogenicity of a live oral bivalent typhoid fever (Salmonella typhi Ty21a)-cholera (Vibrio cholerae CVD 103-HgR) vaccine in healthy adults. Infect. Immun. 63:1995;1336-1339.
43. Lagos R., Fasano A., Wasserman S.S., et al. Effect of small bowel overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR. J. Infect. Dis. 180:1999;1709-1712.
44. Taylor D.N., Rizzo J., Meza R., et al. Cholera among Americans living in Peru. Clin. Infect. Dis. 22:1996;1108-1109.
45. Berger S.A., Shapiro I. Re-emergence of cholera vaccine. J. Travel Med. 4:1997;58-60.
46. Levine M.M., Tacket C.O. Live oral vaccines against cholera. Ala'Aldeen D.A.A., Hormaeche C.E. Molecular and clinical aspects of bacterial vaccine development. 1995;233-258 Wiley, Chichester.
47. Clemens J., Sack D., Rao M., et al. The design and analysis of cholera vaccine trials: recent lessons from Bangladesh. Int. J. Epidemiol. 22:1993;724-730.
48. Clemens J., Harris J., Sack D., et al. Field trial of oral cholera vaccines in Bangladesh: results of one year of follow-up. J. Infect. Dis. 158:1988;60-69.
49. Clemens J.D., Sack D.A., Harris J.R., et al. Field trial of cholera vaccines in Bangladesh: results from three year follow-up. Lancet. 335:1990;270-273.
50. Taylor DN, Cardenas V, Sanchez JL et al. Two-year study of the protective efficacy of the oral whole cell plus recombinant B subunit (WC/rBS) cholera vaccine in Peru. J Infect Dis 2000 (in press).
51. Levine M.M., Taylor D.N., Ferreccio C. Typhoid vaccines come of age. Pediatr. Infect. Dis. J. 8:1989;374-381.
52. Rennels M.B., Glass R.I., Dennehy P.H., et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines - report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group. Pediatrics. 97:1996;7-13.
53. Eskola J., Kayhty H., Takala A.K., et al. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. New Engl. J. Med. 323:1983;1381-1387.
54. Ward J., Brenneman G., Letson G.W., Heyward W.L. Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. The Alaska H. influenzae Vaccine Study Group. New Engl. J. Med. 323:1990;1393-1401.
55. Levine M.M., Ferreccio C., Cryz S., Ortiz E. Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet. 336:1990;891-894.
56. Simanjuntak C., Paleologo F., Punjabi N., et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet. 338:1991;1055-1059.